Bladder Cancer from MIBC to Metastasis
– An Integrated Approach to
Personalized Treatment Optimization –
2 SGMO & SGU Credits*
March 24-26, 2025 & May 14-15, 2025
Prof. Dr. Enrique Grande
* Credits granted for St. Gallen, Rapperswil & Lugano, credits requested for Bern & Lausanne
- Mar 24, 2025, 6:00 PM – 8:00 PMEventhouse, Neue Jonastrasse 65, 8640 Rapperswil-Jona, Switzerland
- Mar 25, 2025, 6:00 PM – 8:00 PMKSSG, Haus 06, 4. Stock, Rorschacher Str. 95, 9000 St. Gallen, Switzerland
- Mar 26, 2025, 6:00 PM – 8:00 PMHotel Dante, Piazza Cioccaro 5, 6900 Lugano, Switzerland
What to expect
Session 1: Mastering the Perioperative Setting in MIBC
-
Systemic Perioperative Treatment of MIBC | Enrique Grande
-
Clinical Case Presentation
Session 2: Exploring 1L Treatment Options in mUC
-
Beyond One Size Fits All: Navigating 1L Treatment Options | Enrique Grande
-
Clinical Case Presentation
Session 3: Advancing 2L Treatment Strategies in mUC
-
Emerging Trends in 2L Treatment | Enrique Grande
-
Clinical Case Presentation
About Prof. Dr. Enrique Grande

Prof. Enrique Grande, MD, PhD, Msc, is the Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Cancer Center Madrid. Prof. Grande focuses on the research on Genitourinary and Endocrine tumors and takes active collaboration in the development of the Translational Research and Early Drug Development Unit.
Prof. Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). A published author of more than 300 manuscripts in peer-reviewed journals, Prof. Grande is also the founder of the Spanish Group for Research on Orphan and Uncommon Tumours (GETHI). Prof. Grande is editor of several international journals and has participated in the most recent trials in the field of bladder cancer that led to the approval of new drugs we have now available and co-chairs the steering committee of the IMVIGOR 130 trial, DISCUS, VOLGA and DV001.
Abbreviations: 1L, first-line; 2L, second-line; MIBC, muscle-invasive bladder cancer; mUC, metastatic urothelial carcinoma.